Novel treatments for Parkinson’s disease

ABSTRACT: Parkinson's disease (PD) is a progressive neurodegenerative disorder associated with a rapidly rising global disease burden and a substantial decline in patients' quality of life. Although currently approved therapies offer symptomatic relief, their clinical efficacy inevitably wanes over time. This review provides a comprehensive summary of recent advancements in both symptomatic treatments and experimental therapies focused on neuroprotection and disease modification. These novel treatments for PD include continuous dopaminergic stimulation, adaptive deep brain stimulation, transcranial temporal interference stimulation, anti-α-synuclein immunotherapies, oral anti-α-synuclein therapies, non-receptor tyrosine kinase inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, iron chelators, fecal microbiota transplantation, glucosylceramide synthase inhibitors, as well as stem cell therapies and gene therapies. However, the majority of these novel treatments are still in the investigational phase and necessitate additional validation via randomized controlled trials. Future research should also focus on optimizing trial methodologies, including the timing of intervention, stratification of PD subjects, and selection of treatment endpoints.